Vaxess Technologies, developer of a shelf-stable vaccine patch, announced today that it named Steve Bende as its new chief strategy officer. Bende previously served as global head of new products at Sanofi Pasteur. He led international, multifunctional teams at the pharmaceutical giant. That included assessing the commercial viability of potential new products. Prior to Sanofi, […]
Vaxess Technologies
Interim data supports Vaxess shelf-stable flu vaccine patch
Vaxess Technologies today announced positive interim results from a first-in-human trial of its influenza vaccine patch. Cambridge, Massachusetts-based Vaxess evaluated VX-103, a monovalent seasonal influenza vaccine patch. The trial included 45 healthy patients and evaluated the H1N1 influenza antigen from Vaxess’ partner, GC Biopharma. Delivery of the vaccine took place through the Vaxess Mimix patch. […]
Vaxess Technologies raises $2M for its silk-based vaccine delivery through the skin
Vaxess Technologies today filed an SEC Form D to confirm the sale of $2 million in debt, options, warrants or other rights to buy securities. According to the filing, three investors contributed to the new notice offering, which made its first sale on Monday, March 22, 2021, before reaching its total offering amount of $2 […]
Vaxess Technologies lands $6m for microneedle vaccines
Vaxess Technologies said today that it won 2 grants from the Bill & Melinda Gates Foundation totalling up to $6 million for the development of inactivated polio and live attenuated measles rubella vaccines using the company’s Mimix sustained-release microneedle patch technology. The company’s Mimix technology is designed for sustained, transdermal delivery of vaccines and inmmunotherapies, […]
